Cancer Services

Dáil Éireann Debate, Thursday - 2 October 2025

• Debates
• Find a debate
  • Dáil debates
  • Seanad debates
  • Committee debates
• Find a vote
  • Dáil votes
  • Seanad votes
  • Committee votes
• Parliamentary questions
  • Written questions
  • Oral questions
• Search tips
• Utterances having an adverse effect

Thursday, 2 October 2025

Questions (455)

Ken O'Flynn

Question:

455. Deputy Ken O'Flynn asked the Minister for Health if her Department has entered into outcomes-based or risk-sharing agreements with pharmaceutical companies in respect of new cancer drugs; and if so, to provide details of the drugs concerned, the duration of the agreements, and the outcomes being measured. [52826/25]

Written answers

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

• Previous Answer
• Next Answer